0A4K trade ideas
SET YOUR SALE LIMIT HIGH. THIS THING IS GOING UP!Set it high, squeeze incoming... hold the line bulls! who gave you the right to short a stock that is trying to save kids who are dying from genetic diseases ?
Continuing the trend.I've added to my long position on this trade now totaling 900 shares.
Hopefully this one is textbook.
Someone is Shorting this... to either accumulate or to protectits either to drive price down to accumulate or to protect an option contract. either way i think the chart is solid and it should bounce back next week to a potential new AH. Gl to all hang in their bulls. it's only a matter of time until their machine is mainstream.
chart is intact...rough day... should move up in the next two days and into next week... gme and amc really have thrown a wrench in most names but as i always say.... the story hasn't changed just the headline. buy the fear.
Clear pattern still intact...AH then retrace, New AH then retrace to previous AH... Currently we are retracing before a new AH possibly mid next week. Tough day in the market today... These are the days the winners stop talking about diamond hands and demonstrate it... Sack Up, its anyones guess how the market will preform tomorrow... Blame two failing Brick and Mortar stocks for a massive market correction who would have thunk it... only in 2021! GL to all...
Will Science Beat the WallStreet Pros.?Chart trend looks intact. From 2nd lvl. looks like someone is suppressing the price either to accumulate or to secure their option position? either way looks like we go up.
Chart is worthless when Parabolic...Instead of a channel I prefer a trend line thru the heart of the chart. Huge catalysts coming up, could be $20+ in a blink... GL to all.
$BNGO PRICE TARGETSBNGO PT
Q1 25$
Q2 35$
Q3 50$
Q4 75$
2022 120$
2023 300$
Once in a lifetime oppurtunity don't miss out, genomics will be the leading sector in market gains.
DNA ReconstructionAlright team i want you to keep this channel in mind as we progress through another Green Week!
I am predicting this price will maintain within this channel moving forward.
As you can see now it is doing a good job staying within !
Penny stocks are always volatile. However The revolutionary technology this company is bringing to the table is outstanding
I am sure a lot of you already researched it and know this ! so i wont get into it.
Keep in mind Buy low & NEVER SELL!
Follow me for technical analysis!
All of this is only opinion and my own personal journal.
None of this is financial advice !
& if you dont plan on holding long term. Dont bother putting your money in this market.
Every Decade you get one.While everyone is chasing the "next thing" or focussing on short squeezes and pump and dumps... Quietly BNGO has emerged from the depths of penny land. While analysts will attempt to scare you out of this stock by touting a 1000%+ run, and touting it as a penny stock similar to ZOM, a look a little closer reveals the company is just retouching its IPO price from two years ago. This is far from a P&D or a GME Short Squeeze hype play (I am all for the GME play, F' Citron) instead this is a new monetization play with some of the smartest Scientists on earth backing it. Stop and think for a second... Why am I chasing a crowded EV play, its TSLA or nothing, why am I chasing a mature e-commerce play like ETSY or Amazon, why am I chasing a MJ play in a foggy market, why am I chasing a mature fin-tech play, why am I chasing a SPAC above $12. If you are looking for true growth you must search for a market that has yet to be monetized. For the next decade the monetization of the human genome will be the largest growth play on earth. I think we have a winner. It's time to yell BINGO! Sale your car, house, child, sale your body, kidney almost anything you can to buy more shares of this. The moon is imminent. ST PT $25 by March 2021. LT PT $415 by March 2023. FANG will go BANG!
Looks like a winner! 15 is coming $75 ST-PTWait for $75 to take a little profit... multi-decade growth story... No one was buying AMZN @ $8 or TSLA @ $25.... Seems the crew on board BNGO is a very much like a cult... good luck trying to short or steal shares from these longs... guys look like fort knox. long and strong. $15 soon...
$BNGO retraced to supportHello traders, investors, masters, and apprentices. Let's take a look at BNGO, one of the hottest genomic stocks at the moment. They have been rallying on the good news of their Saphyr system for optical genome mapping (bit.ly). Today the price headed against the IPO opening price but could not break it.
In the after hour trading, this piece of news was released: "Bionano Genomics Inc. on Tuesday announced its second share sale in less than a month amid an unexplained spike in its price and volume, sending shares down in after-hours trading. Bionano did not disclose a targeted number of shares nor price in its offering, but the stock still fell more than 8% in the extended session. Bionano previously sold 29 million shares at $3.05 a share less than two weeks ago, as shares traded on the open market for more than $5. The stock has since continued to ride higher, closing at an all-time high of $9.14 Tuesday. Bionano shares traded for less than $1 for much of 2020, before prices..." (on.mktw.net)
Well, despite the fall (mainly on account of the news, I believe), BNGO is on a very bullish trend so it seems like this may be a good opportunity to get in because the price dropped to a historic level that was strong resistance in the past (white rectangle) and would likely become support now. That level is also our first fib retracement. There is a good chance the price will hold there. BNGO rallied over 1000% the past month and the indicators on the monthly, weekly, and daily still show bullishness. I am most likely entering a position tomorrow. I have traded BNGO a couple of times the past week for some decent profit. If this support holds it may be an opportunity to start a long term position. Price could obviously fall from here but I think it is worth keeping an eye on this one and see how it reacts to the support tomorrow.
Daily chart:
Share the love:
If you get anything out of this TA, please like the chart so it moves up and others can benefit from my work. A simple click on the like button goes a long ways.
Follow for more:
I have an outstanding winning rate (check my other charts). If you want the best entry/exits just follow me, you won't regret. Thanks a lot!
***The ideas shared here are my opinion, not financial advise to place trades. Please do your own research before buying/selling stocks***
Oppenheimer Analyst Says buy, following of some positive dataOppenheimer 5-star Analyst Says BioNano Genomics is ready to Execute in 2021.
the latest move was decidedly upbeat. In Wednesday’s session, the stock took off to the tune of 40% following the publication of some positive data.
article which made side-by-side comparisons between Bionano’s optical genome mapping platform Saphyr and PacBio's HiFi chemistry revealed that Saphyr had the upper hand on several metrics.
Across 32 different human genomes, PacBio technologies found only 72% of the large SVs (structural variants) that Bionano’s optical genome mapping (OGM) detected.
Saphyr was also found to be better at locating indels in regions correlated to neurodevelopment.
Additionally, Saphyr appears to be more cost effective. The platform’s estimated cost of $500 per genome coming in far below the $10,000-20,000 per genome when HiFi and SMRT sequencing are put into action.
Oppenheimer’s Kevin DeGeeter believes the data should help Saphyr make further inroads in the “large SV research market.” The analyst views 2021 “largely as an execution year.”
We expect the data to support broader adoption of Saphyr for de novo sequencing and research applications. the 5-star analyst said.
“Furthermore, we expect 2021 to be an important year for adoption of Saphyr for clinical cytogenetics market based on a series of positive recent publications... Based on our current assessment of the competitive landscape, we do not believe long-read sequencing technologies can replicate Saphyr's performance and cost structure for digital cytogenetics testing.”
Accordingly, DeGeeter reiterated an Outperform (i.e. Buy) on BNGO shares, along with a $1.5 price target. The implication for investors? Strong upside of 113% .
Two other analysts have thrown the hat in with a BNGO review recently, one saying Buy and the other recommending a Hold -- all add up to a Moderate Buy consensus rating. Meanwhile, the average price target stands at $1.42, implying gains of 101% could be in the cards over the next 12 months.
finance.yahoo.com
BNGO: Bullish pennant, confirmedBullish Pennant, confirmed
Pros:
Descending volume during formation
Volume increase at break out
PPS above 50MA and 200MA
ATR Ascending
R/R ratio above 8
250RSI above 50
200MA ascending
RS above 0, and ascending
Target:
PT = 12.26$
